Interactions of human complement with virus particles containing the Nipah virus glycoproteins

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 5940-5948

  Johnson, John B ^a   Aguilar, Hector C ^b   Lee, Benhur ^b   Parks, Griffith D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; EPHRIN B2; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NIPAH VIRUS; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PSEUDOTYPING; SERUM; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL LINE; CERCOPITHECUS AETHIOPS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT SYSTEM PROTEINS; EPHRIN-B2; GLYCOPROTEINS; HUMANS; NEUTRALIZATION TESTS; NIPAH VIRUS; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRION;

ANIMALIA; HARNESS; NIPAH VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79958128595     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00193-11     Document Type: Article

References (37)

1. Aguilar, H. C., et al. 2006. N-Glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 80:4878-4889.
2. Aguilar, H. C., et al. 2007. Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. 81:4520-4532.
3. Aguilar, H. C., et al. 2009. A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J. Biol. Chem. 284:1628-1635.
4. Blue, C. E., O. B. Spiller, and D. J. Blackbourn. 2004. The relevance of complement to virus biology. Virology 319:176-184.
5. Bolger, M. S., et al. 2007. Complement levels and activity in the normal and LPS-injured lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:L748-L759.
6. Bonaparte, M. I., et al. 2005. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc. Natl. Acad. Sci. U. S. A. 102:10652- 10657.
7. Bossart, K. N., and C. C. Broder. 2006. Developments towards effective treatments for Nipah and Hendra virus infection. Expert Rev. Anti Infect. Ther. 4:43-55.
8. Bossart, K. N., et al. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 5:e1000642.
9. Carroll, M. C. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986.
10. Chung, K. M., et al. 2006. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory factor H. Proc. Natl. Acad. Sci. U. S. A. 103:19111.
11. Eaton, B. T., C. C. Broder, D. Middleton, and L. F. Wang. 2006. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4:23-25.
12. Feng, J. O., K. Mozdzanowska, and W. Gerhard. 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutininspecific antibodies depending on their fine antigen specificity and heavychain isotype. J. Virol. 76:1369-1378.
13. Guillaume, V., et al. 2004. Nipah virus: vaccination and passive protection studies in a hamster model. J. Virol. 78:834-840.
14. Homaira, N., et al. 2010. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh. Epidemiol. Infect. 138:1630-1636.
15. Idusogie, E. E., et al. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2571-2575.
16. Johnson, J. B., G. A. Capraro, and G. D. Parks. 2008. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376:112-123.
17. Johnson, J. B., K. Grant, and G. D. Parks. 2009. The paramyxoviruses simianvirus 5 and mumps virus recruit host cell CD46 to evade complementmediated neutralization. J. Virol. 83:7602-7611.
18. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion of human pathogens. Nat. Rev. Microbiol. 6:132-142.
19. Lee, B. 2007. Envelope-receptor interactions in Nipah virus pathobiology. Ann. N. Y. Acad. Sci. 1102:51-65.
20. Lo, M. K., and P. A. Rota. 2008. The emergence of Nipah virus, a highly pathogenic paramyxovirus. J. Clin. Virol. 43:396-400.
21. McSharry, J. J., R. J. Pickering, and L. A. Caliguiri. 1981. Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology 114:507-515.
22. Mehlhop, E., A. Fuchs, M. Engle, and M. S. Diamond. 2009. Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology 383:11-15.
23. Mehlhop, E., et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-391.
24. Mills, B. J., and N. R. Cooper. 1978. Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements. J. Immunol. 121:1549-1557.
25. Morrison, T. E., R. J. Fraser, P. N. Smith, S. Mahalingam, and M. T. Heise. 2007. Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J. Virol. 81:5132-5143.
26. Mungall, B. A., et al. 2006. Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 80: 12293-12302.
27. Natsume, A. M., et al. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68:3863-3872.
28. Negrete, O. A., et al. 2005. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436:401-405.
29. Porotto, M., et al. 2010. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. 6:e1001168.
30. Roozendaal, R., and M. C. Carroll. 2006. Emerging patterns in complementmediated pathogen recognition. Cell 125:29-32.
31. Schauber-Plewa, C., A. Simmons, M. J. Tuerk, C. D. Pacheco, and G. Veres. 2005. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther. 12: 238-245.
32. Tamin, A., et al. 2009. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 160:1-6.
33. Vasantha, S., et al. 1988. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology 167:433-441.
34. Wang, L., et al. 2001. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3:279-287.
35. Weingartl, H. M., et al. 2006. Recombinant Nipah virus vaccines protect pigs against challenge. J. Virol. 80:7929-7938.
36. Welsh, Jr., R. M. 1977. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J. Immunol. 118:348-354.
37. Zhu, Z., et al. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197:846-853.